"The roles of contract manufacture organizations (CMOs) are becoming more and more important. They create critical values to the biotech ecosystem by providing access to capacity with lower investment, helping reduce overall operation risk and time to market, and making it possible for biologics companies to focus on the higher value research and development. However, the biologics manufacturing is a technologically complex, highly regulated process and the CMO landscape for biologics is relatively undeveloped, especially in mammalian
cell technologies. Pressures from competition in fast product delivery to the market and pricing have made CMO in Asian countries a very attractive business solution."

Objective1: Provide overview on current and future biologics manufacturing capacity and demand.

Objective2: Discuss the drivers and concerns to use CMOs in Asia.

Objective3: Discuss current platform technology development in biologics CMOs.